Quadrant Capital Group LLC Increases Holdings in NeoGenomics, Inc. (NASDAQ:NEO)

Posted by on Feb 27th, 2023

Quadrant Capital Group LLC increased its holdings in NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) by 149.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,027 shares of the medical research company’s stock after buying an additional 1,814 shares during the quarter. Quadrant Capital Group LLC’s holdings in NeoGenomics were worth $26,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of NEO. Ronald Blue Trust Inc. acquired a new position in NeoGenomics in the 2nd quarter worth approximately $28,000. Security Benefit Life Insurance Co. KS acquired a new position in NeoGenomics in the 2nd quarter worth approximately $44,000. Captrust Financial Advisors increased its holdings in NeoGenomics by 17.1% in the 2nd quarter. Captrust Financial Advisors now owns 5,780 shares of the medical research company’s stock worth $47,000 after buying an additional 844 shares during the period. Bessemer Group Inc. acquired a new position in NeoGenomics in the 3rd quarter worth approximately $69,000. Finally, Capstone Financial Advisors Inc. acquired a new position in NeoGenomics in the 2nd quarter worth approximately $82,000. Institutional investors and hedge funds own 88.15% of the company’s stock.

NeoGenomics Trading Down 5.1 %

Shares of NEO stock opened at $15.78 on Monday. The stock’s fifty day moving average is $11.38 and its two-hundred day moving average is $10.30. The company has a debt-to-equity ratio of 0.54, a quick ratio of 6.82 and a current ratio of 6.73. The firm has a market capitalization of $1.99 billion, a P/E ratio of -13.60 and a beta of 1.18. NeoGenomics, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $21.94.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. SVB Leerink increased their price target on shares of NeoGenomics from $12.00 to $15.00 and gave the stock an “outperform” rating in a report on Wednesday, November 9th. Benchmark raised shares of NeoGenomics from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Friday. Cowen dropped their price objective on shares of NeoGenomics to $17.00 in a research note on Tuesday, November 15th. Raymond James raised their price objective on shares of NeoGenomics from $12.00 to $19.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, StockNews.com raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Saturday. Five research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, NeoGenomics presently has a consensus rating of “Moderate Buy” and an average target price of $19.17.

NeoGenomics Company Profile

(Get Rating)

NeoGenomics, Inc is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups.

Read More

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.